SCHEMBL6895418

SCHEMBL6895418

CCc1cc(O)c2c3c(C(=O)OC)cccc3n(Cc3cccc(F)c3)c2c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.45
MAPT P10636 2/20 0.45
LMNA P02545 3/20 0.44
GLA P06280 1/20 0.44
POLB P06746 2/20 0.41
TP53 P04637 1/20 0.41
F10 P00742 2/20 0.40
KDM4E B2RXH2 3/20 0.40
GAA P10253 2/20 0.40
STAT1 P42224 1/20 0.40
RAB9A P51151 1/20 0.40
HSP90AA1 P07900 1/20 0.39
HSP90B1 P14625 1/20 0.39
GRIN1 Q05586 3/20 0.38
GRIN2B Q13224 3/20 0.38
ALDH1A1 P00352 2/20 0.38
HPGD P15428 2/20 0.38
MAPK1 P28482 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HSD17B10 Q99714 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6889327 0.91 MAPT (0.41) L3MBTL1MAPTLMNAGLAPOLB
SCHEMBL6689284 0.91 L3MBTL1 (0.49) L3MBTL1MAPTLMNAGLAPOLB
SCHEMBL6688534 0.90 MAPT (0.45) L3MBTL1MAPTLMNAGLAPOLB
SCHEMBL6894814 0.89 MAPT (0.44) L3MBTL1MAPTLMNAKDM4EGAA
SCHEMBL6774816 0.89 LMNA (0.43) L3MBTL1MAPTLMNAGLAPOLB
SCHEMBL6889689 0.89 MAPT (0.47) L3MBTL1MAPTPOLBTP53F10
SCHEMBL6897173 0.88 MAPT (0.44) L3MBTL1MAPTLMNAGLAPOLB
SCHEMBL6895193 0.88 POLB (0.39) L3MBTL1MAPTPOLBF10GAA
SCHEMBL6893888 0.88 PLA2G2A (0.47) MAPTLMNAPOLBTP53ALDH1A1
SCHEMBL6897981 0.87 PPARG (0.45) L3MBTL1MAPTF10KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6713645-B1 INHIBITING SPLA2 MEDIATED RELEASE OF FATTY ACIDS FOR TREATMENT OF CONDITIONS SUCH AS SEPTIC SHOCK ELI LILLY AND COMPANY 2004-03-30 US disclosed
US-6177440-B1 THERAPY FOR SEPSIS SHOCK; PHOSPHOLIPASE INHBITOR ELI LILLY AND COMPANY 2001-01-23 US disclosed
EP-0952149-A2 Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors ELI LILLY AND COMPANY (US) 1999-10-27 EP disclosed